In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
Ketamine for Depression Read More »
Hewa Artin, Sean Bentley, Eamonn Mehaffey, Fred X. Liu, Kevin Sojourner, Andrew W. Bismark, David Printz, Ellen E. Lee, Brian Martis, Sharon De Peralta, Dewleen G. Baker, Jyoti Mishra, Dhakshin Ramanathan Published 6 May 2022 | https://doi.org/10.1016/j.eclinm.2022.101439 Abstract Background (S)-ketamine is a glutamatergic drug with potent and rapid acting effects for the treatment of depression.
C. Sophia Albott, Kelvin O. Lim, Christopher Erbes, Paul Thuras, Joseph Wels, Susanna J.Tye, Paulo R. Shiroma Published 14 April 2022 | https://doi.org/10.1016/j.jad.2022.04.066 Abstract Background The glutamate N-methyl-d-aspartate (NMDA) receptor antagonist ketamine rapidly ameliorates posttraumatic stress disorder (PTSD) and depression symptoms in individuals with comorbid PTSD and major depressive disorder (MDD). However, concerns over ketamine’s
In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
N.B. clinic brings psychedelic drug to mainstream to treat PTSD Read More »
Chadi G. Abdallah, John D. Roache, Ralitza Gueorguieva, Lynnette A. Averill, Stacey Young-McCaughan, Paulo R. Shiroma, Prerana Purohit, Antoinette Brundige, William Murff, Kyung-Heup Ahn, Mohamed A. Sherif, Eric J. Baltutis, Mohini Ranganathan, Deepak D’Souza, Brenda Martini, Steven M. Southwick, Ismene L. Petrakis, Rebecca R. Burson, Kevin B. Guthmiller, Argelio L. López-Roca, Karl A. Lautenschlager, John
In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
How ketamine therapy helped this Canadian veteran Read More »
Paulo R. Shiroma, MD; Paul Thuras, PhD; Joseph Wels, MD; Christopher Erbes, PhD; Shannon Kehle-Forbes, PhD; and Melissa Polusny, PhD Published 10 November 2020 | https://doi.org/10.4088/JCP.20l13406 Abstract Prolonged exposure (PE) is a gold-standard trauma-focused therapy; however, clinical trials of trauma-based therapies in the military and veteran populations showed that up to 50% of participants failed
Adriana Feder, Sarah B. Rutter, Daniela Schiller, Dennis S.Charney Published 19 June 2020 | https://doi.org/10.1016/bs.apha.2020.05.004 Abstract A serious lack of effective pharmacotherapeutic interventions for posttraumatic stress disorder (PTSD) raises the urgent need for the development of novel treatments. Ketamine—a noncompetitive glutamate N-methyl-d-aspartate (NMDA) receptor antagonist in use for decades as an anesthetic and analgesic agent—has
The emergence of ketamine as a novel treatment for posttraumatic stress disorder Read More »
In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
Ketamine to Treat Depression: A Veteran’s Story Read More »
In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
Ketamine for Veterans for PTSD Read More »